[N05AL01, sulpiride, The therapeutic efficacy of Sulpiride can be increased when used in combination with Dexlansoprazole.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Dexlansoprazole.]
[L01CB02, teniposide, The metabolism of Teniposide can be decreased when combined with Dexlansoprazole.]
[B01AE07, dabigatran etexilate, Dexlansoprazole can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[G03BA03, testosterone, The metabolism of Testosterone can be decreased when combined with Dexlansoprazole.]
[A04AD10, dronabinol, The metabolism of Dexlansoprazole can be decreased when combined with Dronabinol.]
[N05CA19, thiopental, The metabolism of Thiopental can be decreased when combined with Dexlansoprazole.]
[N05AC02, thioridazine, The metabolism of Thioridazine can be decreased when combined with Dexlansoprazole.]
[B03AB03, sodium ironedetate, Dexlansoprazole can cause a decrease in the absorption of Sodium feredetate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B01AC05, ticlopidine, The metabolism of Dexlansoprazole can be decreased when combined with Ticlopidine.]
[S01ED01, timolol, The metabolism of Timolol can be decreased when combined with Dexlansoprazole.]
[N06AF04, tranylcypromine, The metabolism of Dexlansoprazole can be decreased when combined with Tranylcypromine.]
[N03AC02, trimethadione, The metabolism of Trimethadione can be decreased when combined with Dexlansoprazole.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be decreased when combined with Dexlansoprazole.]
[J01FA08, troleandomycin, The metabolism of Dexlansoprazole can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, The metabolism of Vilazodone can be decreased when combined with Dexlansoprazole.]
[A10BH05, linagliptin, The metabolism of Dexlansoprazole can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Dexlansoprazole can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Dexlansoprazole can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, Dexlansoprazole can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C08DA01, verapamil, The metabolism of Dexlansoprazole can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Dexlansoprazole can be decreased when combined with Viloxazine.]
[S01AA13, fusidic acid, The metabolism of Dexlansoprazole can be decreased when combined with Fusidic acid.]
[J05AE02, indinavir, Dexlansoprazole can cause a decrease in the absorption of Indinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M05BA05, tiludronic acid, The therapeutic efficacy of Tiludronic acid can be decreased when used in combination with Dexlansoprazole.]
[L01ED01, crizotinib, The metabolism of Dexlansoprazole can be decreased when combined with Crizotinib.]
[R03DC01, zafirlukast, The metabolism of Dexlansoprazole can be decreased when combined with Zafirlukast.]
[A02BC04, rabeprazole, The metabolism of Rabeprazole can be decreased when combined with Dexlansoprazole.]
[M05BA06, ibandronic acid, The therapeutic efficacy of Ibandronate can be decreased when used in combination with Dexlansoprazole.]
[N05AE04, ziprasidone, The metabolism of Dexlansoprazole can be decreased when combined with Ziprasidone.]
[J02AC03, voriconazole, The metabolism of Dexlansoprazole can be decreased when combined with Voriconazole.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Dexlansoprazole.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Dexlansoprazole.]
[V03AX03, cobicistat, The metabolism of Dexlansoprazole can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Dexlansoprazole can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Dexlansoprazole can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, Dexlansoprazole can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05CA04, barbital, The metabolism of Barbital can be decreased when combined with Dexlansoprazole.]
[J05AE04, nelfinavir, The serum concentration of Nelfinavir can be decreased when it is combined with Dexlansoprazole.]
[G04BE03, sildenafil, The metabolism of Dexlansoprazole can be decreased when combined with Sildenafil.]
[B01AF02, apixaban, The metabolism of Apixaban can be decreased when combined with Dexlansoprazole.]
[M04AB03, benzbromarone, The metabolism of Dexlansoprazole can be decreased when combined with Benzbromarone.]
[R02AD01, benzocaine, The metabolism of Benzocaine can be decreased when combined with Dexlansoprazole.]
[L01EC02, dabrafenib, The serum concentration of Dexlansoprazole can be decreased when it is combined with Dabrafenib.]
[B03AB04, ferric hydroxide, Dexlansoprazole can cause a decrease in the absorption of Ferric hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C02KX05, riociguat, Dexlansoprazole can cause a decrease in the absorption of Riociguat resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N06AX26, vortioxetine, The metabolism of Vortioxetine can be decreased when combined with Dexlansoprazole.]
[N03AF04, eslicarbazepine, The metabolism of Dexlansoprazole can be decreased when combined with Eslicarbazepine.]
[D01AC18, luliconazole, The serum concentration of Dexlansoprazole can be increased when it is combined with Luliconazole.]
[J05AP05, simeprevir, The metabolism of Dexlansoprazole can be decreased when combined with Simeprevir.]
[V03AE05, sucroferric oxyhydroxide, Dexlansoprazole can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A16AA07, metreleptin, The metabolism of Dexlansoprazole can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Dexlansoprazole can be increased when combined with Apremilast.]
[L04AC11, siltuximab, The metabolism of Dexlansoprazole can be increased when combined with Siltuximab.]
[B01AA07, acenocoumarol, The metabolism of Acenocoumarol can be decreased when combined with Dexlansoprazole.]
[V03AE01, polystyrene sulfonate, The therapeutic efficacy of Tolevamer can be decreased when used in combination with Dexlansoprazole.]
[J01XA05, oritavancin, The metabolism of Dexlansoprazole can be decreased when combined with Oritavancin.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Dexlansoprazole.]
[V03AE08, ferric citrate, Dexlansoprazole can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A06AG02, bisacodyl, The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Dexlansoprazole.]
[L04AC10, secukinumab, The metabolism of Dexlansoprazole can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The absorption of Palbociclib can be decreased when combined with Dexlansoprazole.]
[J05AP06, asunaprevir, Dexlansoprazole can cause a decrease in the absorption of Asunaprevir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02BC03, lansoprazole, The metabolism of Dexlansoprazole can be decreased when combined with Lansoprazole.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Dexlansoprazole.]
[J02AC05, isavuconazole, The metabolism of Dexlansoprazole can be decreased when combined with Isavuconazole.]
[L01XX52, venetoclax, The metabolism of Dexlansoprazole can be decreased when combined with Venetoclax.]
[N07BC01, buprenorphine, The metabolism of Dexlansoprazole can be decreased when combined with Buprenorphine.]
[P01BE02, artemether, The metabolism of Artemether can be decreased when combined with Dexlansoprazole.]
[M02AA03, clofezone, The metabolism of Rabeprazole can be decreased when combined with Dexlansoprazole.]
[L01XK03, rucaparib, The metabolism of Dexlansoprazole can be decreased when combined with Rucaparib.]
[L01EF02, ribociclib, The metabolism of Dexlansoprazole can be decreased when combined with Ribociclib.]
[J05AE09, tipranavir, The metabolism of Dexlansoprazole can be decreased when combined with Tipranavir.]
[L04AB02, infliximab, The metabolism of Dexlansoprazole can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Dexlansoprazole can be decreased when combined with Midostaurin.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Dexlansoprazole.]
[J05AG03, efavirenz, The metabolism of Dexlansoprazole can be decreased when combined with Efavirenz.]
[R03BA02, budesonide, Dexlansoprazole can cause a decrease in the absorption of Budesonide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J05AX18, letermovir, The metabolism of Dexlansoprazole can be increased when combined with Letermovir.]
[C09AA01, captopril, Dexlansoprazole can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L02BB05, apalutamide, The serum concentration of Dexlansoprazole can be increased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Dexlansoprazole can be increased when combined with Carbamazepine.]
[N03AX24, cannabidiol, The metabolism of Cannabidiol can be decreased when combined with Dexlansoprazole.]
[L01XX62, ivosidenib, The metabolism of Dexlansoprazole can be increased when combined with Ivosidenib.]
[N03AX17, stiripentol, The metabolism of Dexlansoprazole can be decreased when combined with Stiripentol.]
[J05AX24, tecovirimat, The metabolism of Dexlansoprazole can be decreased when combined with Tecovirimat.]
[L01EB07, dacomitinib, Dexlansoprazole can cause a decrease in the absorption of Dacomitinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M03BA02, carisoprodol, The metabolism of Carisoprodol can be decreased when combined with Dexlansoprazole.]
[L04AA39, emapalumab, The metabolism of Dexlansoprazole can be increased when combined with Emapalumab.]
[P02BX04, triclabendazole, The metabolism of Dexlansoprazole can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The metabolism of Esketamine can be decreased when combined with Dexlansoprazole.]
[J01FA09, clarithromycin, The metabolism of Dexlansoprazole can be decreased when combined with Clarithromycin.]
[N05BA09, clobazam, The metabolism of Clobazam can be decreased when combined with Dexlansoprazole.]
[L04AB01, etanercept, The metabolism of Dexlansoprazole can be increased when combined with Etanercept.]
[L01EM03, alpelisib, The metabolism of Dexlansoprazole can be decreased when combined with Alpelisib.]
[L01EX15, pexidartinib, The serum concentration of Pexidartinib can be decreased when it is combined with Dexlansoprazole.]
[S01AA27, cefuroxime, The serum concentration of Cefuroxime can be decreased when it is combined with Dexlansoprazole.]
[L01EJ02, fedratinib, The metabolism of Fedratinib can be decreased when combined with Dexlansoprazole.]
[N07XX11, pitolisant, The serum concentration of Dexlansoprazole can be decreased when it is combined with Pitolisant.]
[B06AX03, voxelotor, The metabolism of Voxelotor can be decreased when combined with Dexlansoprazole.]
[N03AX25, cenobamate, The serum concentration of Dexlansoprazole can be decreased when it is combined with Cenobamate.]
[H02CA02, osilodrostat, The metabolism of Dexlansoprazole can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Dexlansoprazole can be decreased when combined with Amprenavir.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Dexlansoprazole.]
[C08CA16, clevidipine, The metabolism of Dexlansoprazole can be decreased when combined with Clevidipine.]
[C01BD07, dronedarone, The metabolism of Dexlansoprazole can be decreased when combined with Dronedarone.]
[S03AA08, chloramphenicol, The metabolism of Dexlansoprazole can be decreased when combined with Chloramphenicol.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Dexlansoprazole.]
[L01EX22, selpercatinib, The serum concentration of Selpercatinib can be decreased when it is combined with Dexlansoprazole.]
[P01BB01, proguanil, The metabolism of Proguanil can be decreased when combined with Dexlansoprazole.]
[L04AC19, satralizumab, The serum concentration of Dexlansoprazole can be decreased when it is combined with Satralizumab.]
[B06AC06, berotralstat, The metabolism of Dexlansoprazole can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Dexlansoprazole can be decreased when combined with Lonafarnib.]
[P03AX07, abametapir, The serum concentration of Dexlansoprazole can be increased when it is combined with Abametapir.]
[N03AX10, felbamate, The metabolism of Dexlansoprazole can be decreased when combined with Felbamate.]
[V08CA07, ferric ammonium citrate, Dexlansoprazole can cause a decrease in the absorption of Ferric ammonium citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V03AB31, prussian blue insoluble, Dexlansoprazole can cause a decrease in the absorption of Prussian blue resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AB02, iron sucrose, Dexlansoprazole can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA02, ferrous fumarate, Dexlansoprazole can cause a decrease in the absorption of Ferrous fumarate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA03, ferrous gluconate, Dexlansoprazole can cause a decrease in the absorption of Ferrous gluconate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA06, ferrous succinate, Dexlansoprazole can cause a decrease in the absorption of Ferrous succinate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA07, ferrous sulfate, Dexlansoprazole can cause a decrease in the absorption of Ferrous sulfate anhydrous resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[R03CC15, formoterol, The metabolism of Formoterol can be decreased when combined with Dexlansoprazole.]
[B03AB10, ferric maltol, Dexlansoprazole can cause a decrease in the absorption of Ferric maltol resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02BA01, cimetidine, The metabolism of Dexlansoprazole can be decreased when combined with Cimetidine.]
[L01XX73, sotorasib, The therapeutic efficacy of Sotorasib can be decreased when used in combination with Dexlansoprazole.]
[L01EN03, infigratinib, The serum concentration of Infigratinib can be decreased when it is combined with Dexlansoprazole.]
[S03AA07, ciprofloxacin, The metabolism of Dexlansoprazole can be decreased when combined with Ciprofloxacin.]
[N06AB04, citalopram, The risk or severity of QTc prolongation can be increased when Dexlansoprazole is combined with Citalopram.]
[H01AC07, somapacitan, The metabolism of Dexlansoprazole can be decreased when combined with Somapacitan.]
[L04AA48, belumosudil, The serum concentration of Belumosudil can be decreased when it is combined with Dexlansoprazole.]
[P01CA03, fexinidazole, The metabolism of Fexinidazole can be decreased when combined with Dexlansoprazole.]
[L01XX74, belzutifan, The metabolism of Belzutifan can be decreased when combined with Dexlansoprazole.]
[N06AX25, St. John's wort extract, The metabolism of Dexlansoprazole can be increased when combined with St. John's Wort.]
[L01EA06, asciminib, The metabolism of Dexlansoprazole can be decreased when combined with Asciminib.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be decreased when combined with Dexlansoprazole.]
[N06AA04, clomipramine, The metabolism of Dexlansoprazole can be decreased when combined with Clomipramine.]
[C01EB24, mavacamten, The serum concentration of Mavacamten can be increased when it is combined with Dexlansoprazole.]
[A02BC08, vonoprazan, The metabolism of Dexlansoprazole can be decreased when combined with Vonoprazan.]
[N05AH02, clozapine, The metabolism of Dexlansoprazole can be decreased when combined with Clozapine.]
[H01AC08, somatrogon, The metabolism of Dexlansoprazole can be increased when combined with Somatrogon.]
[L04AC21, bimekizumab, The metabolism of Dexlansoprazole can be increased when combined with Bimekizumab.]
[J01FA15, telithromycin, The metabolism of Dexlansoprazole can be decreased when combined with Telithromycin.]
[J02AC02, itraconazole, Dexlansoprazole can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01EA01, imatinib, The metabolism of Imatinib can be decreased when combined with Dexlansoprazole.]
[J02AC04, posaconazole, Dexlansoprazole can cause a decrease in the absorption of Posaconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02BC05, esomeprazole, The metabolism of Dexlansoprazole can be decreased when combined with Esomeprazole.]
[C08CA11, manidipine, The metabolism of Dexlansoprazole can be decreased when combined with Manidipine.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Dexlansoprazole.]
[S01XA18, cyclosporine, The metabolism of Dexlansoprazole can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, The metabolism of Moclobemide can be decreased when combined with Dexlansoprazole.]
[N06BA07, modafinil, The metabolism of Dexlansoprazole can be decreased when combined with Modafinil.]
[S01XA21, cysteamine, The bioavailability of Cysteamine can be decreased when combined with Dexlansoprazole.]
[C03XA02, conivaptan, The metabolism of Dexlansoprazole can be decreased when combined with Conivaptan.]
[M01AH05, etoricoxib, The metabolism of Dexlansoprazole can be decreased when combined with Etoricoxib.]
[G03XA01, danazol, The metabolism of Dexlansoprazole can be decreased when combined with Danazol.]
[C07AB12, nebivolol, The metabolism of Nebivolol can be decreased when combined with Dexlansoprazole.]
[N06AX06, nefazodone, The metabolism of Dexlansoprazole can be decreased when combined with Nefazodone.]
[L02BB02, nilutamide, The metabolism of Dexlansoprazole can be decreased when combined with Nilutamide.]
[N06AB10, escitalopram, The metabolism of Escitalopram can be decreased when combined with Dexlansoprazole.]
[N03AF02, oxcarbazepine, The metabolism of Dexlansoprazole can be decreased when combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The metabolism of Dexlansoprazole can be increased when combined with Dexamethasone.]
[L04AB04, adalimumab, The metabolism of Dexlansoprazole can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, Dexlansoprazole can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N06BA02, dextroamphetamine, Dexlansoprazole can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N06AB05, paroxetine, The metabolism of Paroxetine can be decreased when combined with Dexlansoprazole.]
[B01AC04, clopidogrel, The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Dexlansoprazole resulting in a loss in efficacy.]
[N05BA01, diazepam, The metabolism of Diazepam can be decreased when combined with Dexlansoprazole.]
[M05BA02, clodronic acid, The therapeutic efficacy of Clodronic acid can be decreased when used in combination with Dexlansoprazole.]
[L01EB02, erlotinib, Dexlansoprazole can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C08CA03, isradipine, The metabolism of Dexlansoprazole can be decreased when combined with Isradipine.]
[J05AE08, atazanavir, Dexlansoprazole can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C08DB01, diltiazem, The metabolism of Dexlansoprazole can be decreased when combined with Diltiazem.]
[M02AX03, dimethyl sulfoxide, The metabolism of Dexlansoprazole can be decreased when combined with Dimethyl sulfoxide.]
[N06BA11, dexmethylphenidate, Dexlansoprazole can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[S02AA12, rifamycin SV, The metabolism of Dexlansoprazole can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Dexlansoprazole can be increased when combined with Rifapentine.]
[A04AD12, aprepitant, The metabolism of Dexlansoprazole can be decreased when combined with Aprepitant.]
[L01XG01, bortezomib, The metabolism of Dexlansoprazole can be decreased when combined with Bortezomib.]
[J05AE07, fosamprenavir, Dexlansoprazole can cause a decrease in the absorption of Fosamprenavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N06AA16, dothiepin, The metabolism of Dexlansoprazole can be decreased when combined with Dosulepin.]
[N06AA12, doxepin, The metabolism of Doxepin can be decreased when combined with Dexlansoprazole.]
[J01AA02, doxycycline, Dexlansoprazole can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N06AB06, sertraline, The metabolism of Sertraline can be decreased when combined with Dexlansoprazole.]
[N03AX11, topiramate, The metabolism of Dexlansoprazole can be decreased when combined with Topiramate.]
[C08CA12, mepirodipine, The metabolism of Dexlansoprazole can be decreased when combined with Barnidipine.]
[N05CF02, zolpidem, The metabolism of Zolpidem can be decreased when combined with Dexlansoprazole.]
[N03AX15, zonisamide, The metabolism of Dexlansoprazole can be decreased when combined with Zonisamide.]
[N02CA02, ergotamine, The metabolism of Dexlansoprazole can be decreased when combined with Ergotamine.]
[N03AG01, valproic acid, The metabolism of Dexlansoprazole can be decreased when combined with Valproic acid.]
[S01AA17, erythromycin, The metabolism of Dexlansoprazole can be decreased when combined with Erythromycin.]
[A02BC02, pantoprazole, The metabolism of Dexlansoprazole can be decreased when combined with Pantoprazole.]
[G03CA03, estradiol, The metabolism of Estradiol can be decreased when combined with Dexlansoprazole.]
[J04AK02, ethambutol, The metabolism of Dexlansoprazole can be decreased when combined with Ethambutol.]
[L02AA03, ethinyl estradiol, The metabolism of Dexlansoprazole can be decreased when combined with Ethinylestradiol.]
[L04AD02, tacrolimus, The metabolism of Tacrolimus can be decreased when combined with Dexlansoprazole.]
[R06AX12, terfenadine, The metabolism of Dexlansoprazole can be decreased when combined with Terfenadine.]
[N06AB08, fluvoxamine, The metabolism of Dexlansoprazole can be decreased when combined with Fluvoxamine.]
[M05BA01, etidronic acid, The therapeutic efficacy of Etidronic acid can be decreased when used in combination with Dexlansoprazole.]
[P02CA03, albendazole, The metabolism of Albendazole can be decreased when combined with Dexlansoprazole.]
[J02AC01, fluconazole, The metabolism of Dexlansoprazole can be decreased when combined with Fluconazole.]
[V03AZ01, ethanol, The metabolism of Dexlansoprazole can be decreased when combined with Ethanol.]
[N06AB03, fluoxetine, The metabolism of Dexlansoprazole can be decreased when combined with Fluoxetine.]
[J05AE10, darunavir, The metabolism of Dexlansoprazole can be decreased when combined with Darunavir.]
[M05BA04, alendronic acid, The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Dexlansoprazole.]
[C10AB04, gemfibrozil, The metabolism of Dexlansoprazole can be decreased when combined with Gemfibrozil.]
[L01EA02, dasatinib, Dexlansoprazole can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J05AG04, etravirine, The metabolism of Etravirine can be decreased when combined with Dexlansoprazole.]
[N03AD03, methsuximide, The metabolism of Methsuximide can be decreased when combined with Dexlansoprazole.]
[L01EH01, lapatinib, The metabolism of Lapatinib can be decreased when combined with Dexlansoprazole.]
[A10BB01, glyburide, The metabolism of Glyburide can be decreased when combined with Dexlansoprazole.]
[A10BB09, gliclazide, The metabolism of Gliclazide can be decreased when combined with Dexlansoprazole.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be decreased when combined with Dexlansoprazole.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Dexlansoprazole.]
[C09CA01, losartan, The metabolism of Dexlansoprazole can be decreased when combined with Losartan.]
[A07EC02, mesalamine, Dexlansoprazole can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05CA16, hexobarbital, The metabolism of Hexobarbital can be decreased when combined with Dexlansoprazole.]
[C08CA10, nilvadipine, The metabolism of Dexlansoprazole can be decreased when combined with Nilvadipine.]
[J04AB04, rifabutin, The metabolism of Dexlansoprazole can be increased when combined with Rifabutin.]
[M05BA07, risedronic acid, Dexlansoprazole can cause an increase in the absorption of Risedronic acid resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N06AA02, imipramine, The metabolism of Dexlansoprazole can be decreased when combined with Imipramine.]
[N06AX17, milnacipran, The metabolism of Dexlansoprazole can be decreased when combined with Milnacipran.]
[N05CH02, ramelteon, The metabolism of Ramelteon can be decreased when combined with Dexlansoprazole.]
[J04AC01, isoniazid, The metabolism of Dexlansoprazole can be decreased when combined with Isoniazid.]
[L04AC07, tocilizumab, The metabolism of Dexlansoprazole can be increased when combined with Tocilizumab.]
[J02AB02, ketoconazole, Dexlansoprazole can cause a decrease in the absorption of Ketoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H02CA04, levoketoconazole, Dexlansoprazole can cause a decrease in the absorption of Levoketoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05AH03, olanzapine, The metabolism of Dexlansoprazole can be decreased when combined with Olanzapine.]
[L04AA24, abatacept, The metabolism of Dexlansoprazole can be increased when combined with Abatacept.]
[C07AG01, labetalol, The metabolism of Labetalol can be decreased when combined with Dexlansoprazole.]
[N03AX18, lacosamide, The metabolism of Lacosamide can be decreased when combined with Dexlansoprazole.]
[N06BA13, armodafinil, The metabolism of Dexlansoprazole can be decreased when combined with Armodafinil.]
[C10AA02, lovastatin, The metabolism of Dexlansoprazole can be decreased when combined with Lovastatin.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be decreased when combined with Dexlansoprazole.]
[L01EA03, nilotinib, The serum concentration of Nilotinib can be decreased when it is combined with Dexlansoprazole.]
[N06DX01, memantine, Dexlansoprazole may decrease the excretion rate of Memantine which could result in a higher serum level.]
[N03AB04, mephenytoin, The metabolism of Dexlansoprazole can be decreased when combined with Mephenytoin.]
[N03AA01, mephobarbital, The metabolism of Methylphenobarbital can be decreased when combined with Dexlansoprazole.]
[N07BC02, methadone, The metabolism of Methadone can be decreased when combined with Dexlansoprazole.]
[J01XX05, methenamine, The therapeutic efficacy of Methenamine can be decreased when used in combination with Dexlansoprazole.]
[H03BB02, methimazole, The metabolism of Dexlansoprazole can be decreased when combined with Methimazole.]
[L04AX03, methotrexate, The excretion of Methotrexate can be decreased when combined with Dexlansoprazole.]
[V04CG05, methylene blue, The metabolism of Methylene blue can be decreased when combined with Dexlansoprazole.]
[N06BA04, methylphenidate, Dexlansoprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[S02AA13, miconazole, The metabolism of Dexlansoprazole can be decreased when combined with Miconazole.]
[L01XX23, mitotane, The metabolism of Dexlansoprazole can be increased when combined with Mitotane.]
[C01BD01, amiodarone, The metabolism of Dexlansoprazole can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be decreased when combined with Dexlansoprazole.]
[L04AB05, certolizumab pegol, The metabolism of Dexlansoprazole can be increased when combined with Certolizumab pegol.]
[L01EX03, pazopanib, Dexlansoprazole can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AA06, mycophenolic acid, Dexlansoprazole can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J05AJ01, raltegravir, Dexlansoprazole can cause an increase in the absorption of Raltegravir resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N03AB05, fosphenytoin, The metabolism of Dexlansoprazole can be increased when combined with Fosphenytoin.]
[V03AB15, naloxone, The metabolism of Dexlansoprazole can be decreased when combined with Naloxone.]
[L04AC03, anakinra, The metabolism of Dexlansoprazole can be increased when combined with Anakinra.]
[N06BA01, amphetamine, Dexlansoprazole can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[L02BG04, letrozole, The metabolism of Dexlansoprazole can be decreased when combined with Letrozole.]
[N06AX23, desvenlafaxine, The metabolism of Dexlansoprazole can be decreased when combined with Desvenlafaxine.]
[C09CA07, telmisartan, The metabolism of Dexlansoprazole can be decreased when combined with Telmisartan.]
[C08CA04, nicardipine, The metabolism of Dexlansoprazole can be decreased when combined with Nicardipine.]
[H01CB02, octreotide, Dexlansoprazole can cause a decrease in the absorption of Octreotide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AC04, rilonacept, The metabolism of Dexlansoprazole can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Dexlansoprazole can be decreased when combined with Omeprazole.]
[V08CB01, ferumoxsil, Dexlansoprazole can cause a decrease in the absorption of Ferumoxsil resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05CA01, pentobarbital, The metabolism of Dexlansoprazole can be increased when combined with Pentobarbital.]
[N03AA02, phenobarbital, The metabolism of Dexlansoprazole can be increased when combined with Phenobarbital.]
[N03AB02, phenytoin, The metabolism of Dexlansoprazole can be increased when combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Dexlansoprazole can be increased when combined with Golimumab.]
[J05AE01, saquinavir, The serum concentration of Saquinavir can be increased when it is combined with Dexlansoprazole.]
[J01DD16, cefditoren, The serum concentration of Cefditoren can be decreased when it is combined with Dexlansoprazole.]
[J05AG02, delavirdine, Dexlansoprazole can cause a decrease in the absorption of Delavirdine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AC08, canakinumab, The metabolism of Dexlansoprazole can be increased when combined with Canakinumab.]
[J05AE03, ritonavir, The serum concentration of Dexlansoprazole can be increased when it is combined with Ritonavir.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be decreased when combined with Dexlansoprazole.]
[P01BA03, primaquine, The metabolism of Dexlansoprazole can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Dexlansoprazole can be increased when combined with Primidone.]
[C10AB05, fenofibrate, The metabolism of Dexlansoprazole can be decreased when combined with Fenofibrate.]
[G03DA04, progesterone, The metabolism of Progesterone can be decreased when combined with Dexlansoprazole.]
[C07AA05, propranolol, The metabolism of Propranolol can be decreased when combined with Dexlansoprazole.]
[P01BC01, quinine, The metabolism of Quinine can be decreased when combined with Dexlansoprazole.]
[J04AB02, rifampin, Dexlansoprazole can cause a decrease in the absorption of Rifampicin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
